AI-based pathology classifier predicts sensitivity to enzalutamide in metastatic hormone-sensitiv...

https://pubmed.ncbi.nlm.nih.gov/42360803/

Of 1,125 ENZAMET participants, 492 had eligible digitized tissue; 316 were APIC-negative and 176 APIC-positive. Treatment-by-biomarker interaction for overall survival was significant (P=0.014). Enzalutamide versus conventional nonsteroidal antiandrogen produced HR 0.50 (95% CI 0.35–0.73) and 60-month OS 76.5% versus 58.3% in APIC-negative disease, but HR 1.04 (0.67–1.62) and 55.6% versus 58.8% in APIC-positive disease. The low-volume interaction was also significant (P=0.015).